Azithromycin Suspension Solicitation
Closed Pre-Solicitation Posted
This opportunity was awarded. See the award notice from , or the latest solicitation from .
- Solicitation number
- SPE2D2-25-R-0001
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical Supply Chain is preparing to issue a national requirements contract for Azithromycin Suspension, seeking to establish a supply source for pharmaceutical products across multiple federal agencies. The solicitation will cover three specific bottle sizes of Azithromycin Suspension (200MG/5ML in 15ML, 22.5ML, and 30ML), which will be used by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements-type agreement with a one-year base period and four potential one-year option periods. This is a fully competitive, commercial item acquisition processed under FAR Part 12, meaning all sources may submit proposals for consideration. The current projected solicitation date is October 2024, with a proposal due date of December 2, 2024, and interested parties are encouraged to contact Kahaun Vicks at (215-737-0652) or kahaun.vicks@dla.mil for any questions.
The procurement is an unrestricted acquisition with no specific set-aside designations, indicating broad market participation is welcome. While specific award values are not detailed in the pre-solicitation notice, the contract is designed to serve as a national supply source with potential significant volume across multiple federal agencies. The solicitation documents will include annual usage estimates in the Schedule of Supplies, which will help potential vendors understand anticipated demand. Contractors will be evaluated on their ability to provide the specified Azithromycin Suspension products consistently and meet the requirements of a national requirements contract. The contract will be posted on both the DLA Bid Board System (DIBBS) and SAM.gov, providing transparent access to all potential bidders. Interested parties are advised to establish automated notifications through the respective websites to track any updates or changes to the solicitation.
Notice text
3 versions
Update #3 · Latest ·
Amendment to extend closing date attached.
Update #2 ·
Solicitation attached.
Update #1 ·
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Azithromycin Suspension. Procurement details follow.
Azithromycin Suspension 200MG/5ML 15ML, 200MG/5ML 22.5ML and 200MG/5MG 30ML bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and SAM.gov at https://sam.gov. Interested parties should contact Kahaun Vicks (215-737-0652) (kahaun.vicks@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is October of 2024. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
Files
| File | Type | Posted |
|---|---|---|
| SPE2D225R00010001_Sol extended to 18.Dec.2024.pdf | ||
| Azithromycin Suspension Solicitation.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Azithromycin Suspension Award | Award Notice | |
| Azithromycin Suspension Solicitation | Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| 6505--Sodium Bicarbonate Injection Vial Restricted to Made in America | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity